Lee Ainslie Biogen Inc. Transaction History

Maverick Capital LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $356,144 - $428,704	1,600 New	1,600 $414,000
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $270,570 - $312,652	983 New	983 $280,000
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $696,839 - $895,540	-3,112 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $880,664 - $1.15 Million	3,112 New	3,112 $881,000
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $339,269 - $510,684	-1,436 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $811,520 - $937,001	-3,065 Reduced 68.1%	1,436 $407,000
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $1.16 Million - $1.54 Million	4,501 New	4,501 $1.2 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $1.08 Million - $1.5 Million	-4,919 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $1.07 Million - $1.2 Million	4,919 New	4,919 $1.15 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.